Verastem Q4 adjusted EPS beats analyst expectations

Reuters03-05

<a href="https://laohu8.com/S/VSTM">Verastem</a> Q4 adjusted EPS beats analyst expectations

Overview

Adjusted EPS for Q4 beat analyst expectations

Outlook

Verastem expects cash runway into first half of 2027

Result Drivers

FDA APPROVAL IMPACT - AVMAPKI FAKZYNJA CO-PACK generated $17.5 mln in Q4 revenue following accelerated FDA approval
INCREASED EXPENSES - Higher operating expenses due to commercialization costs and increased R&D spending

Company press release: ID:nBw9DVShna

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted EPS	Beat	-$0.48	-$0.53 (9 Analysts)
Q4 Net Income		-$32.92 mln
Q4 Income from Operations		-$41.47 mln
Q4 Operating Expenses		$59.009 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Verastem Inc is $17.00, about 199.3% above its March 3 closing price of $5.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617569631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617569631","market":"us","top_or_hot":-1,"title":"Verastem Q4 adjusted EPS beats analyst expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Q4 adjusted EPS beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Verastem expects cash runway into first half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FDA APPROVAL IMPACT - AVMAPKI FAKZYNJA CO-PACK generated $17.5 mln in Q4 revenue following accelerated FDA approval</p></li><li><p>INCREASED EXPENSES - Higher operating expenses due to commercialization costs and increased R&amp;D spending</p></li></ul><p>Company press release: <span>ID:nBw9DVShna</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.48</p></td><td><p>-$0.53 (9 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$32.92 mln</p></td><td></td></tr><tr><td><p>Q4 Income from Operations</p></td><td></td><td><p>-$41.47 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$59.009 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Verastem Inc is $17.00, about 199.3% above its March 3 closing price of $5.68</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Q4 adjusted EPS beats analyst expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Q4 adjusted EPS beats analyst expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Q4 adjusted EPS beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Verastem expects cash runway into first half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FDA APPROVAL IMPACT - AVMAPKI FAKZYNJA CO-PACK generated $17.5 mln in Q4 revenue following accelerated FDA approval</p></li><li><p>INCREASED EXPENSES - Higher operating expenses due to commercialization costs and increased R&amp;D spending</p></li></ul><p>Company press release: <span>ID:nBw9DVShna</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.48</p></td><td><p>-$0.53 (9 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$32.92 mln</p></td><td></td></tr><tr><td><p>Q4 Income from Operations</p></td><td></td><td><p>-$41.47 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$59.009 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Verastem Inc is $17.00, about 199.3% above its March 3 closing price of $5.68</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL1N3ZS1AX:1","article_id":"2617569631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617569631","pubTimestamp":1772658810,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verastem Q4 adjusted EPS beats analyst expectationsOverviewAdjusted EPS for Q4 beat analyst expectationsOutlookVerastem expects cash runway into first half of 2027Result DriversFDA APPROVAL IMPACT - A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"Verastem第四季度调整后每股收益超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":0.9},"content_text":"Verastem Q4 adjusted EPS beats analyst expectationsOverviewAdjusted EPS for Q4 beat analyst expectationsOutlookVerastem expects cash runway into first half of 2027Result DriversFDA APPROVAL IMPACT - AVMAPKI FAKZYNJA CO-PACK generated $17.5 mln in Q4 revenue following accelerated FDA approvalINCREASED EXPENSES - Higher operating expenses due to commercialization costs and increased R&D spendingCompany press release: ID:nBw9DVShnaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Adjusted EPSBeat-$0.48-$0.53 (9 Analysts)Q4 Net Income-$32.92 mlnQ4 Income from Operations-$41.47 mlnQ4 Operating Expenses$59.009 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Verastem Inc is $17.00, about 199.3% above its March 3 closing price of $5.68For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617569631","isCrawlerRequest":true}